Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System
21 Junho 2023 - 5:00AM
Business Wire
The world’s most connected continuous glucose
monitoring system,† Dexcom G6, is now the first and only CGM to
connect with the Omnipod® 5 Automated Insulin Delivery (AID) System
in the United Kingdom.
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time
continuous glucose monitoring for people with diabetes, today
announced the Dexcom G6 Real-Time Continuous Glucose Monitoring
System (rt-CGM) is the first and only CGM to connect to the
Omnipod® 5 AID System, helping users to protect against high and
low glucose levels1,2.
“For over a decade, Dexcom has been the sensor of choice for the
development of AID systems. Dexcom has supported more than 50
studies around the world ranging from early academic projects to
increasingly sophisticated trials in collaboration with industry
partners, safely powering AID systems for over 1 million
patient-years of cumulative use. Our CGM systems were the first to
enable industry-leading connectivity and we now link with over 60
connected partners worldwide,” said Teri Lawver, Executive Vice
President, Chief Commercial Officer at Dexcom.
By adding another AID product to its CGM ecosystem, Dexcom has
both strengthened its position as the world’s most connected CGM,
with the Dexcom G6, and offered yet another AID choice to those
living with type 1 diabetes in the U.K.
“At Dexcom we believe that diabetes technology should be built
to celebrate and support the diabetes community. This launch gives
Dexcom users in the U.K. another choice in automated insulin
delivery systems, adding to the company’s existing insulin delivery
collaborations with Tandem, Ypsomed and CamDiab. We are delighted
to see years of close collaboration with industry partners result
in giving people with diabetes unparalleled choice, peace of mind
and better clinical outcomes,” said Ben Byrne, Country Director for
the U.K. and Ireland at Dexcom.
Emphasising Dexcom’s position as a leader in integrating
connected systems, Dexcom G6 was exclusively used in the clinical
trials that led to the regulatory approval of Omnipod 5® in Europe
and the United States.1,2 As a result, the clinically meaningful
health outcomes resulting from the use of Omnipod 5® are only
proven when the system is connected to Dexcom CGM. In a study
published in Diabetes Care,1 Dexcom G6 with Omnipod 5®
significantly improved time in range and reduced HbA1c and time in
hypoglycaemia (<70 mg/dL) in very young children (aged 2 – 5.9
years) with Type 1 diabetes.
As the world’s most connected CGM†, Dexcom is committed to
providing users with choice and flexibility when it comes to how
they view their glucose data and deliver insulin 2-8. Dexcom CGM is
also integrated with the Tandem t:slim X2 and YpsoMed mylife
YpsoPump insulin pumps; digital health apps including Glooko, nudg,
Happy Bob and Sugarmate, and most recently, lifestyle devices from
Garmin.
To learn more about how Dexcom G6 offers the widest range of AID
solutions for users and HCPs, visit Dexcom.com.
About Dexcom G6
Dexcom G6 uses a small, wearable sensor and transmitter to
continuously measure and send glucose levels wirelessly to a smart
device* or receiver, giving patients real-time glucose data without
the need to scan or prick their finger.‡ The system has
customisable and predictive alerts and alarms to help avoid
potentially dangerous low and high blood sugar events and a
function that allows patients to share their glucose data in real
time with up to 10 followers. § Dexcom G6 also offers
industry-leading connectivity through integrations with leading
insulin delivery systems and digital health apps.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
about Dexcom CGM, visit www.dexcom.com.
*Smart devices sold separately. For a list of compatible
devices, visit dexcom.com/en-GB/compatibility and
omnipod.com/compatibility. † Data on file 2022. ‡ Fingersticks
required for diabetes treatment decisions if symptoms or
expectations do not match readings. §Separate Follow app and
internet connection required. Users should always confirm readings
on the Dexcom G6 app or receiver before making treatment
decisions.
1 Sherr J, et al. Diabetes Care 2022;45(8):1907–1910. 2 Brown,
S, et al. Diabetes Care. 2021;44(7):1630–1640. 3 Peacock S, et al.
Diabetes Ther. 2023;14(5):839-855. 4 Boughton CK, et al. Lancet
Healthy Longevity. 2022(3):E135–42. 5 Ware J, et al. N Engl J Med.
2022;386:209–19. 6 Sheng T, et al. American Association of Diabetes
Educators (AADE) Emerging Science Poster, 2019. 7 Sheng T, et al.
Diabetes 2020;69(Supplement_1):861–P. 8. Ringenberger K, et al. J
Endocrine Soc. 2021;5(Supp 1):A32.
Dexcom, Dexcom CGM, Dexcom G6 and any related logos and design
marks are either registered trademarks or trademarks of Dexcom,
Inc. in the United States and/or other countries. ©2023 Dexcom,
Inc. All rights reserved.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230621163124/en/
Media Contacts
United Kingdom Gemma McDonald +44
(0) 7552 368398 gemma.mcdonald@dexcom.com
United States James McIntosh +1
(619) 884-2118 james.mcintosh@dexcom.com
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DexCom (NASDAQ:DXCM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024